{"disease":{"id":"high-risk-neuroblastoma","name":"high risk neuroblastoma"},"drugs":{"marketed":[{"drug_id":"naxitamab","indication_name":"Relapsed or Refractory High-Risk Neuroblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hu3F8","generic_name":"NAXITAMAB","company_name":"Y-Mabs Therapeutics Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Glycolipid Disialoganglioside-directed Antibody [EPC]","quality_score":53,"revenue":null,"mechanism":"Hu3F8 works by binding to a specific glycolipid on cancer cells, marking them for destruction by the immune system."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01041638","title":"Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06057948","title":"A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":94,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03794349","title":"Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":94,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT06831552","title":"Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06858501","title":"Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":84,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT05650749","title":"GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Stephan Grupp MD PhD","has_results":false},{"nct_id":"NCT06528496","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03786783","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":42,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06803875","title":"Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Roberto Chiarle","has_results":false},{"nct_id":"NCT03061656","title":"Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT07007117","title":"PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"Stephan Grupp MD PhD","has_results":false},{"nct_id":"NCT07502287","title":"Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT03165292","title":"Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":34,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT07278674","title":"Clinical Study of Eflornithine After Immunotherapy for High-risk Neuroblastoma（CSHEIN）","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Shanghai Children's Hospital","has_results":false},{"nct_id":"NCT05272371","title":"Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Jagiellonian University","has_results":false},{"nct_id":"NCT04751383","title":"Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04412408","title":"Study on Sintilimab in Stage IV High Risk Neuroblastoma","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Shanghai Children's Medical Center","has_results":false},{"nct_id":"NCT05373901","title":"Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT06182410","title":"Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04501757","title":"Naxitamab and GM-CSF in People With Neuroblastoma","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}